findmyKOL
Clinical trialNCT06773936Enrolling, by, invitationPhase 2Interventional

Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

SponsorSWOG Cancer Research NetworkEnrollment55CD19+ Acute LeukemiaPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Uc Irvine Medical Center

    Orange, California, United States

  • Northwell Health/center for Advanced Medicine

    Lake Success, New York, United States

  • University of Rochester Medical Center

    Rochester, New York, United States

  • Duke University Medical Center

    Durham, North Carolina, United States

  • University of Cincinnati Cancer Ctr-Uc Medical Ctr

    Cincinnati, Ohio, United States

  • Cleveland Clinic Foundation

    Cleveland, Ohio, United States

  • Upmc Hillman Cancer Center

    Pittsburgh, Pennsylvania, United States

  • Baptist Memorial Health Care

    Memphis, Tennessee, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
15 May 2026
Primary completion
31 May 2029
Completion
31 Jul 2033
Last update posted
6 May 2026
Registered enrollment
55
Registry id
NCT06773936

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.